Progress in the Comorbidity of Depression and Anxiety

doi:10.3969/j.issn.2095-1396.2017.06.005

Abstract

Abstract:

It is traditionally thought that anxiety disorder and depressive disorder are categorically defined as two individual psychiatric disorders. As clinical practice and epidemiological studies show，however，the comorbidity of depression and anxiety is prevalent and of poorer outcomes than either disorder alone. In this review，the concepts，clinical features，therapeutic managements，and animal models related to the comorbidity of depression and anxiety are well addressed. In addition，establishing the novel animal models and developing the new agents of both anti-depression and-anxiety are discussed to improve its diagnosis，treatment，and medical prevention.

Key words: anxiety, depression, comorbidity, animal model

CLC Number:

R964

Cite this article

LIANG Hui，CHENG Tao，LIANG Jian-hui. Progress in the Comorbidity of Depression and Anxiety[J]. Acta Neuropharmacologica, DOI: 10.3969/j.issn.2095-1396.2017.06.005.

share this article

0
/ Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: http://actanp.hebeinu.edu.cn/EN/10.3969/j.issn.2095-1396.2017.06.005

http://actanp.hebeinu.edu.cn/EN/Y2017/V7/I6/30

References

[1] Tabatha H Melton, Paul E Croarkin, Jeffrey R Strawn, et al. Comorbid anxiety and depressive symptoms in children and adolescents: a systematic review and analysis [J]. J Psychiatr Pract, 2016, 22(2):84-98.

[2] Katharina Kircanski, Joelle LeMoult, Sarah Ordaz, et al. Investigating the nature of cooccurring depression and anxiety: Comparing diagnostic and dimensional research approaches [J]. J Affect Disord, 2017, 16:123-135.

[3] Amanda L Rebar, Rob Stanton, Simon Rosenbaum. Comorbidity of depression and anxiety in exercise research [J]. Lancet Psychiatry, 2017, 4(7): 519.

[4] Alvan R Feinstein. The pre-therapeutic classification of co-morbidity in chronic disease [J]. J Chronic Dis, 1970, 23(7): 455-468.

[5] Jules Angst. Depression and anxiety: implications for nosology, course, and treatment[J]. J Clin Psychiatry, 1997, 58(Suppl 8): 3-5.

[6] Van Praag H M. Comorbidity (psycho) analysed [J]. Br J Psychiatry Suppl, 1996, 30: 129-134.

[7] Ron de Graaf, Rob V Bijl, Filip Smit, et al. Risk factors for 12?month comorbidity of mood, anxiety, and substance use disorders: fndings from the Netherlands Mental Health Survey and Incidence Study [J]. Am J Psychiatry, 2002, 159(4): 620?629.

[8] Robert Johansson, Per Carlbring, Asa Heedman, et al. Depression, anxiety and their comorbidity in the Swedish general population: point prevalence and the effect on health-related quality of life [J]. Peer J, 2013, 1:e98.

[9] Michael R Phillips, Zhang Jing-xuan, Shi Qi-chang, et al. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001?05: An epidemiological survey [J]. Lancet, 2009, 373(9680): 2041?2053.

[10] Arjan W Braam, John R M Copeland, Philippe A E G Delespaul, et al. Depression, subthreshold depression and comorbid anxiety symptoms in older Europeans: results from the EURODEP concerted action [J]. J Affect Disord, 2014, 155: 266-272.

[11] Colleen M Cummings, Nicole E Caporino, Philip C Kendall. Comorbidity of anxiety and depression in children and adolescents: 20 years after [J]. Psychol Bull, 2014, 140(3): 816-845.

[12] Ahmet Koyuncu, Erhan Ertekin, Banu Aslantas Ertekin, et al. Relationship between atypical depression and social anxiety disorder [J]. Psychiatry Res, 2015, 225(1-2): 79-84.

[13] Idan M Aderka, Courtney Beard, Josephine Lee, et al. The relationship between depression and generalized anxiety during intensive psychological and pharmacological treatment [J]. J Affect Disord, 2015, 184: 261-268.

[14] Jesper T Andreasen, Ciaran M Fitzpatrick, Maria Larsen, et al. Differential role of AMPA receptors in mouse tests of antidepressant and anxiolytic action [J]. Brain Res, 2015, 1601: 117-126.

[15] Aravind Mittur. Trazodone: properties and utility in multiple disorders [J]. Expert Rev Clin Pharmacol, 2011, 4(2): 181-196.

[16] Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam [J]. Arch Gen Psychiatry, 1993, 50(11): 884-895.

[17] Fawcett J, Barkin R L. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety [J]. J Clin Psychiatry, 1998, 59(3): 123-127.

[18] Sarawut Lapmanee, Jantarima Charoenphandhu, Narattaphol Charoenphandhu. Beneficial effects of fluoxetine, reboxetine, venlafaxine, and voluntary running exercise in stressed male rats with anxiety- and depression-like behaviors [J]. Behav Brain Res, 2013, 250: 316-325.

[19] Kostowski W, Dyr W, Krzascik P, et al. 5-Hydroxytryptamine1A receptor agonists in animal models of depression and anxiety [J]. Pharmacol Toxicol, 1992, 71(1): 24-30.

[20] Sramek J J, Tansman M, Suri A, et al. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms [J]. J Clin Psychiatry, 1996, 57(7): 287-91.

[21] 王宪军, 王振英.丁螺环酮与文拉法新联合治疗抑郁焦虑共病对照研究[J]. 新乡医学院学报, 2004, 21(5): 407-408.

[22] Richard C Shelton, Gary D Tollefson, Mauricio Tohen, et al. A novel augmentation strategy for treating resistant major depression [J]. Am J Psychiatry, 2001, 158(1):131-134.

[23] 王坚. 从胆论治冠心病后焦虑、抑郁症[J]. 中国社区医师: 医学专业, 2010, 12(7): 93-94.

[24] 李克建，陈云，郭娟，等. 疏肝解郁胶囊联合草酸艾司西酞普兰治疗脑卒中患者焦虑抑郁状态的疗效观察[J]. 国际精神病学杂志, 2017, 44(2): 260-262+266.

[25] 宋波, 朱功蓓, 林煜涵, 等.解虑安神汤对焦虑小鼠脑内GABA水平及其受体表达的影响[J]. 中药药理与临床, 2013, 29(6): 118-121.

[26] 郭岳峰刘方洲. 解郁安神汤抗抑郁作用的实验研究[J]. 中医研究, 2010, 23(10): 24-26.

[27] 尹东辉, 张晶, 刘纯莉. 乌灵胶囊的临床应用进展[J]. 中国新药杂志, 2011, 20(16)：1530-1533+1562

[28] Jean-Philippe Boulenger, M Fournier, D Rosales, et al. Mixed anxiety and depression: from theory to practice[J]. J Clin Psychiatry, 1997, 58(Suppl 8): 27-34.

[29] Colleen Stiles-Shields, Mary J Kwasny, Cai Xuan, et al. Comorbid anxiety as a differential treatment predictor for telephone versus face-to-face administered cognitive behavioral therapy for depression[J]. Depress Anxiety, 2014, 31(11): 934-940.

[30] Dilip Kumar Pandey, Sushil Kumar Yadav, Radhakrishana Mahesh, et al. Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: a model of comorbid depression and anxiety? [J]. Behav Brain Res, 2009, 205(2):436-442.

[31] Liu Yu-ting, Shao Yen-wen, Yen Chen-tung, et al. Acid-induced hyperalgesia and anxio- depressive comorbidity in rats [J]. Physiol Behav, 2014, 131: 105-110.

[32] Kenneth J Sufka, Matthew Feltenstein, Jason E Warnick, et al. Modeling the anxiety-depression continuum hypothesis in domestic fowl chicks [J]. Behav Pharmacol, 2006, 17(8): 681-689.

[33] Ana M Basso, Kelly B Gallagher, Natalie A Bratcher, et al. Antidepressant- like effect of D (2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test [J]. Neuropsy-chopharmacology, 2005, 30(7):1257-1268.

[34] Rodrigo Moraga-Amaro, Hugo Gonzalez, Rodrigo Pacheco, et al. Dopamine receptor D3 deficiency results in chronic depression and anxiety [J]. Behav Brain Res, 2014, 274: 186-193.

[35] Lucien Steru, Raymond Chermat, Bernard Thierry, et al. The tail suspension test: a new method for screening antidepressants in mice [J]. Psychopharmacology (Berl), 1985, 85(3):367-370.

[36] Malika El Yacoubi, Saoussen Bouali, Daniela Popa, et al. Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression [J]. Proc Natl Acad Sci U S A, 2003, 100(10):6227-6232.

[37] Malika El Yacoubi, Virginie Rappeneau, Eddy Champion, et al. The H/Rouen mouse model displays depression-like and anxiety-like behaviors [J]. Behav Brain Res, 2013, 256:43-50.

Catherine S John, Elizaheth I Sypek, William A Carlezon, et al. Blockade of the GLT-1 transporter in the central nucleus of the amygdala induces both anxiety and depressive-like symptoms [J]. Neuropsychopharmacology, 2015, 40(7):1700-1708.

Related Articles 15

[1]	ZHANG Dan-shen，ZHANG Jian-mei. Methods and Evaluation of Animal Models of Induced Pulmonary Tuberculosis [J]. Acta Neuropharmacologica, 2019, 9(6): 11-14.
[2]	ZHANG Dan-shen1，MA Jia-cheng2. Methods and Evaluation of Animal Models of Induced Pulmonary Fibrosis [J]. Acta Neuropharmacologica, 2019, 9(6): 15-20.
[3]	ZHANG Dan-shen，JIN Shan. Methods and Evaluation of Animal Models of Induced Silicosis [J]. Acta Neuropharmacologica, 2019, 9(6): 21-25.
[4]	ZHANG Dan-shen，ZHANG Jian-mei. Methods and Evaluation of Animal Models of Induced Pneumonia [J]. Acta Neuropharmacologica, 2019, 9(5): 17-23.
[5]	ZHANG Dan-shen，LI Jia-ying. Methods and Evaluation of Animal Models of Induced Pulmonary Hypertension [J]. Acta Neuropharmacologica, 2019, 9(5): 24-29.
[6]	ZHANG Dan-shen，LI Lan. Methods and Evaluation of Animal Models of Induced Emphysema [J]. Acta Neuropharmacologica, 2019, 9(5): 30-33.
[7]	ZHANG Dan-shen，WANG Fei-fan. Methods and Evaluation of Animal Models of Induced Pulmonary Edema [J]. Acta Neuropharmacologica, 2019, 9(5): 34-39.
[8]	ZHANG Dan-shen，ZHANG Nan. Methods and Evaluation of Animal Models of Induced Bronchial Asthma [J]. Acta Neuropharmacologica, 2019, 9(4): 1-8.
[9]	DI Tong，ZHAO Zhi-jie，BAO Jin-feng. Preliminary Study on the Effect of Folic Acid on Anxiety-Like Behavior in Adult Mice Induced by Maternal Separation [J]. Acta Neuropharmacologica, 2019, 9(1): 6-12.
[10]	SUN Cheng-cheng，LIU Jian-gang，LIU Mei-xia，LI Hao，LUO Zeng-gang. Exploration of Pathological Mechanism of Vascular Dementia Induced by Chronic Cerebral Hypoperfusion and Production of Several Common Animal Models [J]. Acta Neuropharmacologica, 2019, 9(1): 13-17.
[11]	LI Wei，ZHANG Dan-shen. Methods and Evaluation of Animal Models of Induced Chronic Bronchitis [J]. Acta Neuropharmacologica, 2019, 9(1): 18-22.
[12]	FU Zhi-jiang1，GAO Yun2，ZHANG Wei3，LIU Zong-chao1，4，ZHANG Hua-wen4，LIU Shi-gui1，HUANG Chen-yi1，GAO Yin5，GAO Hai-ming1. Effects and Mechanisms of Depression on Bone Fracture Healing in Rats [J]. Acta Neuropharmacologica, 2018, 8(6): 1-8.
[13]	FU Zhi-jiang1，LIU Yong1，GAO Yin1，ZHANG Wei2，GAO Yun2，LIU Zong-chao1. Effects and Mechanisms of Depression on Bone Fracture Healing in Rats* [J]. Acta Neuropharmacologica, 2018, 8(4): 5-6.
[14]	CHEN Ling1，CHENG Zi-juan2，JIN Ji3，LI Qing-yu1，WANG Gang 1. Inhibition of Phosphodiesterase-2 Activity in the Amygdala Produces Anxiolytic-Like Effects in Mice [J]. Acta Neuropharmacologica, 2018, 8(4): 8-9.
[15]	LIANG Jian-hui1,2, LIANG hui2, CHENG tao1, LIU Xiao-yan1, Simon M.Y.Lee3, TANG Ben-qin3, WANG Xiu-fen3, CHEN Feng4,Andrew J. Lawrence4. Comorbidity of Anxiety and Depression Induced by Liang’s Contextual-Stress Box in Mice* [J]. Acta Neuropharmacologica, 2018, 8(4): 44-45.

Metrics

Viewed

Full text

Abstract

Abstract
References
Related Articles
Recommended Articles
Metrics

TOP